Fig. 4.

Absolute cell counts at week 14 after infliximab or steroid treatment in early and late disease. The change in cell number between baseline and week 14 was calculated in the late rheumatoid arthritis (RA) group receiving infliximab (n = 7), the early RA–infliximab group (n = 11) and the early RA–steroid group (n = 11). Changes were analysed for (a) CD14^bright monocytes, (b) CD14^dim monocytes, (c) CD16⁺ granulocytes and (d) CD3^-CD56⁺ natural killer (NK) cells. Significant differences from baseline to week 14 of treatment were calculated using Wilcoxon's signed rank test. P < 0·05 was considered significant and marked with a star (*).